NRx Pharmaceuticals, Inc. to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
NRx Pharmaceuticals Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application
NRx Pharmaceuticals Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 Following Type C FDA Meeting
HOPE Therapeutics, an NRx Subsidiary Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
NRx Pharmaceuticals Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 Following Type C FDA Meeting
NRx Pharmaceuticals Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
NRx Pharmaceuticals and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
NRx Pharmaceuticals Announces US Food and Drug Administration Receipt of ANDA for KETAFREE, a Preservative-Free IV Ketamine
NRx Pharmaceuticals and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference
